Arginase inhibition by piceatannol-3′-O-β-D-glucopyranoside improves endothelial dysfunction via activation of endothelial nitric oxide synthase in ApoE-null mice fed a high-cholesterol diet

International Journal of Molecular Medicine

Volumn 31, Issue 4, 2013, Pages 803-810

  Woo, Ainieng ^a   Shin, Woosung ^a   Cuong, To Dao ^b   Min, Byungsun ^b   Lee, Jeong Hyung ^a   Jeon, Byung Hwa ^c   Ryoo, Sungwoo ^a  

^a Kangwon National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

Apolipoprotein E null mice; Arginase; Endothelial dysfunction; Endothelial nitric oxide synthase; Piceatannol 3 O D glucopyranoside

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; APOLIPOPROTEIN E; ARGINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOPYRANOSIDE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PICEATANNOL; PICEATANNOL 3' O BETA DEXTRO GLUCOPYRANOSIDE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR FUNCTION; CHOLESTEROL DIET; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASOCONSTRICTION; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; APOLIPOPROTEINS E; ARGINASE; DIET, HIGH-FAT; ENZYME STABILITY; GLUCOSIDES; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; PLAQUE, ATHEROSCLEROTIC; STILBENES; VASOCONSTRICTION;

EID: 84875243340     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1261     Document Type: Article

References (33)

1. Moncada S and Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012, 1993.
2. Ryoo S, Lemmon CA, Soucy KG, et al: Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 99: 951-960, 2006.
3. Ryoo S, Gupta G, Benjo A, et al: Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 102: 923-932, 2008.
4. Matsuda H, Morikawa T, Toguchida I, Park JY, Harima S and Yoshikawa M: Antioxidant constituents from rhubarb: structural requirements of stilbenes for the activity and structures of two new anthraquinone glucosides. Bioorg Med Chem 9: 41-50, 2001.
5. Choi SZ, Lee SO, Jang KU, et al: Antidiabetic stilbene and anthraquinone derivatives from Rheum undulatum. Arch Pharm Res 28: 1027-1030, 2005.
6. Moon MK, Kang DG, Lee JK, Kim JS and Lee HS: Vasodilatory and anti-inflammatory effects of the aqueous extract of rhubarb via a NO-cGMP pathway. Life Sci 78: 1550-1557, 2006.
7. Ngoc TM, Minh PT, Hung TM, et al: Lipoxygenase inhibitory constituents from rhubarb. Arch Pharm Res 31: 598-605, 2008.
8. Choi KH, Kim JE, Song NR, et al: Phosphoinositide-3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc Res 85: 836-844, 2010.
9. Woo A, Min B and Ryoo S: Piceatannol-3′-O-beta-D-glucopyranoside as an active component of rhubarb activates endothelial nitric oxide synthase through inhibition of arginase activity. Exp Mol Med 42: 524-532, 2010.
10. White AR, Ryoo S, Li D, et al: Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 47: 245-251, 2006.
11. Boger RH, Bode-Boger SM, Mugge A, et al: Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 117: 273-284, 1995.
12. Berkowitz DE, White R, Li D, et al: Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108: 2000-2006, 2003.
13. Santhanam L, Lim HK, Miriel V, et al: Inducible NO synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res 101: 692-702, 2007.
14. Maarsingh H, Zaagsma J and Meurs H: Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives. Br J Pharmacol 158: 652-664, 2009.
15. Christianson DW: Arginase: structure, mechanism, and physiological role in male and female sexual arousal. Acc Chem Res 38: 191-201, 2005.
16. Yang Z and Ming XF: Endothelial arginase: a new target in atherosclerosis. Curr Hypertens Rep 8: 54-59, 2006.
17. Wilson AM, Harada R, Nair N, Balasubramanian N and Cooke JP: L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 116: 188-195, 2007.
18. Walker HA, McGing E, Fisher I, et al: Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 38: 499-505, 2001.
19. Blum A, Hathaway L, Mincemoyer R, et al: Oral L-arginine in patients with coronary artery disease on medical management. Circulation 101: 2160-2164, 2000.
20. Ansel GM and Lumsden AB: Evolving modalities for femoropopliteal interventions. J Endovasc Ther 16 (Suppl 2): II82-II97, 2009.
21. Ichinose F, Roberts JD Jr and Zapol WM: Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 109: 3106-3111, 2004.
22. Griffiths MJ and Evans TW: Inhaled nitric oxide therapy in adults. N Engl J Med 353: 2683-2695, 2005.
23. Barbato JE, Kibbe MR and Tzeng E: The emerging role of gene therapy in the treatment of cardiovascular diseases. Crit Rev Clin Lab Sci 40: 499-545, 2003.
24. Kibbe MR and Tzeng E: Nitric oxide synthase gene therapy in vascular pathology. Semin Perinatol 24: 51-54, 2000.
25. Ibengwe JK and Suzuki H: Changes in mechanical responses of vascular smooth muscles to acetylcholine, noradrenaline and high-potassium solution in hypercholesterolemic rabbits. Br J Pharmacol 87: 395-402, 1986.
26. Arthur JF, Yin ZL, Young HM and Dusting GJ: Induction of nitric oxide synthase in the neointima induced by a periarterial collar in rabbits. Arterioscler Thromb Vasc Biol 17: 737-740, 1997.
27. Rupin A, Behr D and Verbeuren TJ: Increased activity of guanylate cyclase in the atherosclerotic rabbit aorta: role of non-endothelial nitric oxide synthases. Br J Pharmacol 119: 1233-1238, 1996.
28. Kawashima S: The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium 11: 99-107, 2004.
29. Ozaki M, Kawashima S, Yamashita T, et al: Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 110: 331-340, 2002.
30. Shi W, Wang X, Shih DM, Laubach VE, Navab M and Lusis AJ: Paradoxical reduction of fatty streak formation in mice lacking endothelial nitric oxide synthase. Circulation 105: 2078-2082, 2002.
31. Closs EI, Scheld JS, Sharafi M and Forstermann U: Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol 57: 68-74, 2000.
32. Simon A, Plies L, Habermeier A, Martine U, Reining M and Closs EI: Role of neutral amino acid transport and protein breakdown for substrate supply of nitric oxide synthase in human endothelial cells. Circ Res 93: 813-820, 2003.
33. Erdely A, Kepka-Lenhart D, Salmen-Muniz R, et al: Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets. PLoS One 5: e15253, 2010.